(Reuters) -Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million.

VANCOUVER, BC / ACCESS Newswire / August 25, 2025 / Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE American:ASM)(FSE:GV6) ...

Share prices for precious metals mining companies finally started responding to higher metal prices. Click here to read more.

Discover why PrairieSky Royalty offers a smarter, lower-risk way to invest in oil through its royalty model and strong ...

The acquisition of seven direct royalties and 33 underlying royalties will give Regal exposure to the Hunter Valley mine’s ...

As per DJE Kapital AG, a leading bank-independent financial services provider, July has often been a favorable month, and ...

Shares in Royalty Pharma ($RPRX) were higher today after snapping up a royalty interest in pharmaceutical group Amgen’s ...

In a report released on August 12, Josh Wolfson from RBC Capital maintained a Buy rating on Osisko Gold Royalties, with a price target of $30.00. The company’s shares closed yesterday at $30.55.

Russell Investments Group Ltd. increased its stake in Osisko Gold Royalties Ltd (NYSE:OR – Free Report) by 5.2% during the fourth quarter, according to its most recent filing with the Securities ...